BeiGene

The Chinese developer of next-generation cancer treatments is raking in huge returns from its flagship drug, but R&D and sales costs keep rising.

BeiGene still bleeding red ink despite blockbuster drug

The Chinese developer of next-generation cancer treatments is raking in huge returns from its flagship drug, but R&D and sales costs keep rising Key Takeaways: The Chinese biotech reported a…
BGNE.US 6160.HK 688235.SHG
The biotech company has been dogged by multiple challenges recently, including declining revenue, ongoing losses and a recent rejection by one of its overseas partners.

Junshi hopes new scientist CEO can cure its woes

The biotech company has been dogged by multiple challenges recently, including declining revenue, ongoing losses and a recent rejection by one of its overseas partners Key Takeaways: Junshi has appointed…
1877.HK 688180.SHG
This biopharma company has marked out a path to profitability by licensing its drug expertise and antibody platforms to partners such as Pfizer.

HBM gets health boost from drug licensing deals

The biopharma company has marked out a path to profitability by licensing its drug expertise and antibody platforms to partners such as Pfizer Key Takeaways: Nona Biosciences, a subsidiary of…
2142.HK
BeiGene has a total of three marketed proprietary products.

FAST NEWS: Beigene stock falls after Novartis terminates partnership

The latest: Cancer drug maker BeiGene Ltd. (BGNE.US; 6160.HK; 668235.SH) announced Tuesday that Novartis (NOVN.SWX) will relinquish its rights to co-develop, produce and commercialize BeiGene’s esophagus cancer drug tislelizumab. Looking up: Novartis will provide…
BGNE.US 6160.HK
BeiGene was slapped with a patent lawsuit by U.S. rival AbbVie in June, and suffered another blow to its global ambitions in July when Novartis pulled out of a drug collaboration.

Sales success comes with side effects for drug maker BeiGene

The Chinese biotech’s product revenues surged nearly 82% in the second quarter, driven by forecast-beating sales of its core cancer drugs Key Takeaways: Global sales of BeiGene's anti-tumor drug zanubrutinib…
BGNE.US 6160.HK

Daylight ahead for China’s battered semiconductor sector?

Interim results from Chinese semiconductor companies suggest change for the better lies ahead for this group   　 By Research-Select Major Chinese microchip maker Hua Hong Semiconductor Ltd. (1347.HK; 688347.SH) went…
1347.HK

Recent Articles

RELATED ARTICLES

  1. BeiGene was slapped with a patent lawsuit by U.S. rival AbbVie in June, and suffered another blow to its global ambitions in July when Novartis pulled out of a drug collaboration.
    Sales success comes with side effects for drug maker BeiGene
    BGNE.US 6160.HK
  2. Heated market for dueling blood cancer drugs lands BeiGene in court
    BGNE.US 6160.HK
  3. Drug maker Junshi seeks Swiss cure for cash woes
    1877.HK 688150.SHG
  4. AstraZeneca pays hefty price for Chinese weight-loss drug
    AZN.US
  5. Akeso marks profit milestone with swift rights issue
    9926.HK
  6. FAST NEWS: Beigene stock falls after Novartis terminates partnership
    BGNE.US 6160.HK
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo File-alt

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva